Abstract:The discovery of broadly protective antibodies to the influenza virus neuraminidase (NA) has raised interest in NA as a vaccine target. However, recombinant, solubilized tetrameric NA ectodomains are often challenging to express and isolate, hindering the study of anti-NA humoral responses. To address this obstacle, we established a panel of 22 non-adherent cell lines stably expressing native, historical N1, N2, N3, N9, and NB NAs anchored on the cell surface. The cell lines are barcoded with fluorescent proteins, enabling high-throughput, 16-plex analyses of antibody binding with commonly available flow cytometers. The cell lines were at least as efficient as a Luminex multiplex binding assay at identifying NA antibodies from a library of unselected clonal IgGs derived from human memory B cells. The membrane-anchored NAs are catalytically active and are compatible with established small-molecule catalytic activity assays. NA-expressing K530 cell lines therefore represent a useful tool for studying NA immunity and evaluating influenza vaccine efficacy.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: how to study the antibody response to influenza virus neuraminidase (NA) more efficiently, especially the technical difficulties encountered in developing broad - spectrum protective antibodies against NA and evaluating the efficacy of influenza vaccines. ### Specific problems and background 1. **Challenges in recombinant soluble NA expression**: - Recombinant, solubilized tetrameric NA extracellular domains are usually difficult to express and purify, which hinders the study of NA antibody responses. Traditional recombinant NA expression methods usually exclude the N - terminal stalk segment and transmembrane region and replace them with the tetramerization domain of other proteins, resulting in extremely low yields (10 to 100 times lower than recombinant HA). 2. **Limitations of existing technologies**: - Methods for expressing full - length NA, such as virus - like particles (VLPs) or transiently transfected mammalian cell lines, are feasible but have problems such as high equipment requirements, being unsuitable for multiplex analysis, and not being suitable for sharing between laboratories. 3. **The need for an efficient NA expression system**: - Researchers need a stable and efficient NA expression system to better study the immunogenicity of NA and evaluate vaccine efficacy. ### Solutions To solve the above problems, researchers have developed a new experimental tool - fluorescent - barcoded K530 cell lines that stably express full - length NA anchored to the cell membrane. Specifically: - **Establishing stable NA - expressing cell lines**: Through genetic engineering, the K530 cell line is made to stably express full - length NA from different historical strains. - **Fluorescent barcoding**: The cell lines are labeled with fluorescent proteins, enabling 16 - plex antibody - binding analysis to be carried out simultaneously. - **High - throughput screening**: Using flow cytometry, the antibody - binding situations of multiple NA subtypes can be detected simultaneously in a single experiment. - **Catalytic activity verification**: It is confirmed that the expressed NA has catalytic activity and can be used for existing small - molecule catalytic activity assays. ### Results and significance By this method, researchers have successfully established 22 cell lines that stably express different NA subtypes and have proven that these cell lines are at least as effective as the Luminex multiplex - binding assay in recognizing NA antibodies. In addition, these cell lines also have catalytic activity and can be used for further functional studies. In summary, this study provides a new, efficient NA expression platform, which helps to accelerate the research on NA - related antibodies and the development of influenza vaccines.

Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases

Expression and Characterization of Recombinant, Tetrameric and Enzymatically Active Influenza Neuraminidase for the Setup of an Enzyme-Linked Lectin-Based Assay

Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge

Increased efficacy of influenza virus vaccine candidate through display of recombinant neuraminidase on virus like particles

Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase

Nanobody-based Sandwich Reporter System for Living Cell Sensing Influenza A Virus Infection.

Development and Characterization of an Antibody That Recognizes Influenza Virus N1 Neuraminidases

High-Yield Expression and Purification of Recombinant Influenza Virus Proteins from Stably-Transfected Mammalian Cell Lines

Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo .

Influenza Virus Carrying a Codon-Reprogrammed Neuraminidase Gene as a Strategy for Live Attenuated Vaccine

A pan-influenza antibody inhibiting neuraminidase via receptor mimicry

Enhancing NA immunogenicity through novel VLP designs

Preparation and identification of antibodies targeting influenza A virus N1 subtype neuraminidase

Structural Convergence and Water-Mediated Substrate Mimicry Enable Broad Neuraminidase Inhibition by Human Antibodies

Targeting neuraminidase: the next frontier for broadly protective influenza vaccines

Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase

The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination

Production of Neuraminidase Virus Like Particles by Stably Transformed Insect Cells: A Simple Process for NA-Based Influenza Vaccine Development

Novel Epitopes of the Influenza Virus N1 Neuraminidase Targeted by Human Monoclonal Antibodies

Structural basis of broad protection against influenza virus by a human antibody targeting the neuraminidase active site via a recurring motif in CDR H3

Immune Effects Against Influenza A Virus and a Novel DNA Vaccine with Co-Expression of Haemagglutinin- and Neuraminidase-Encoding Genes.